Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Int J Mol Sci. 2017 Nov 6;18(11):2342. doi: 10.3390/ijms18112342.
Gliomas are devastating brain cancers that have poor prognostic outcomes for their patients. Short overall patient survival is due to a lack of durable, efficacious treatment options. Such therapeutic difficulties exist, in part, due to several glioma survival adaptations and mechanisms, which allow glioma cells to repurpose paracrine signalling pathways and ion channels within discreet microenvironments. These Darwinian adaptations facilitate invasion into brain parenchyma and perivascular space or promote evasion from anti-cancer defence mechanisms. Ultimately, this culminates in glioma repopulation and migration at distances beyond the original tumour site, which is a considerable obstacle for effective treatment. After an era of failed phase II trials targeting individual signalling pathways, coupled to our increasing knowledge of glioma sub-clonal divergence, combinatorial therapeutic approaches which target multiple molecular pathways and mechanisms will be necessary for better treatment outcomes in treating malignant gliomas. Furthermore, next-generation therapy which focuses on infiltrative tumour phenotypes and disruption of the vascular and perivascular microenvironments harbouring residual disease cells offers optimism for the localised control of malignant gliomas.
神经胶质瘤是一种具有破坏性的脑癌,患者预后较差。患者的总体存活期较短,是因为缺乏持久有效的治疗选择。这种治疗上的困难部分归因于几种神经胶质瘤的生存适应和机制,这些机制使神经胶质瘤细胞能够重新利用旁分泌信号通路和离散微环境中的离子通道。这些达尔文式的适应促进了神经胶质瘤细胞侵入脑实质和血管周围间隙,或逃避抗癌防御机制。最终,这导致神经胶质瘤在远离原发肿瘤部位的地方重新增殖和迁移,这是有效治疗的一个重大障碍。在针对单个信号通路的 II 期临床试验失败之后,再加上我们对神经胶质瘤亚克隆分化的认识不断增加,针对多个分子通路和机制的联合治疗方法将是治疗恶性神经胶质瘤更好的治疗结果所必需的。此外,专注于浸润性肿瘤表型和破坏含有残留肿瘤细胞的血管和血管周围微环境的下一代治疗方法为恶性神经胶质瘤的局部控制带来了希望。